CTXR (Citius Pharmaceuticals Inc. Common) Stock Analysis - Financials

Citius Pharmaceuticals Inc. Common (CTXR) is a publicly traded Healthcare sector company. As of May 21, 2026, CTXR trades at $0.57 with a market cap of $14.47M and a P/E ratio of -0.26. CTXR moved +4.31% today. Year to date, CTXR is -38.29%; over the trailing twelve months it is -21.47%. Its 52-week range spans $0.48 to $13.52. Rallies surfaces CTXR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are CTXR's key financials?

CTXR financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CTXR recently traded at $0.57. Market cap is $14.47M. P/E ratio is -0.26. Revenue is $5.61M.

CTXR Key Metrics

Key financial metrics for CTXR
MetricValue
Price$0.57
Market Cap$14.47M
P/E Ratio-0.26
EPS$-2.24
Dividend Yield0.00%
52-Week High$13.52
52-Week Low$0.48
Volume4.24K
Avg Volume0
Revenue (TTM)$5.61M
Net Income$-55.45M
Gross Margin0.00%

CTXR Annual Financials

YearRevenueNet IncomeEPS
2025$0$-39.74M$-3.38
2024$0$-39.43M$-5.97
2023$0$-32.54M$0.00
2022$0$-33.64M$-0.23

Latest CTXR News

CTXR Analyst Consensus

CTXR analyst coverage data. Average price target: $0.00.

Common questions about CTXR

What are CTXR's key financials?
CTXR financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CTXR recently traded at $0.57. Market cap is $14.47M. P/E ratio is -0.26. Revenue is $5.61M.
Is CTXR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CTXR. It does not provide personalized investment advice.
CTXR

CTXR